syneos-ergi meet manag
synh clinic revenu growth acceler primari catalyst
stock management track achiev merger cost synergi reinvest major
increment amount lt growth opportun begin show
syneos-on revenu captur leverag span synh
servic capabl across clinic commerci rais ep pt
context clinic partnership oncolog win last year disclos
partnership award sponsor chose provid clinic develop servic
oncolog pipelin prior decis pharma larg client
commerci segment consult busi came inventiv manag
indic backlog includ award client revenu ramp
slowli expect common partnership interestingli understood
also done work client management correct second client
chosen oncolog exist client pipelin shift
oncolog chose work select two client reinforc
second multi-therapeut win management disclos second larg partnership
ep call award juli partnership award june backlog
manag expect award client significantli
client alreadi larg commerci custom success cross-sel
client replac exist two vendor two new vendor includ five
reason client identifi synh win abil leverag insight
commerci clinic vice versa therapeut expertis trust process
asia presenc engag senior manag team
defend commerci target despit weaker book commerci grown
ytd includ kinaps inventiv commerci overweight
larg pharma smaller smid revenu base grew book
underwhelm ttm book-to-bil drop june compar
mgt target due cancel guidanc growth
organ impli organ management suggest book target
would produc upsid guidanc commerci get cautiou
book think cushion appropri see disconnect
qualit traction syneoson progress actual book gap close
posit synh multipl narrow gap peer
margin expans higher year management expect bp margin expans
increment synergi reinvest syneoson
larg pharma account management busi develop data digit capabl management
suggest target bp next year compar margin peer carri
higher pass-through cost load iclr pressur margin
function higher smid mix lower mix
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
clinic btb stabil around balanc
win across smid larg pharma
clinic revenu grow mid-singl digit
improv broaden book
commerci revenu aid kinaps acquisit
grow high-singl digit
synergi target achiev slightli earlier
end
clinic book-to-bil move higher
opportun compet larger engag
clinic grow mid-to-high-singl digit
commerci book rebound revenu grow dd
fda approv remain strong
synergi target exceed year
post-clos run-rat end year
momentum book-to-bil fall
clinic grow low singl digit despit strong
book low-to-mid singl digit
organ
margin expans limit cost synergi
run-rat end
discount peer largest margin safeti
investor
compet effect larg partnership
opportun one believ could top
pharma revenu stream
confid manag achiev cost synergi
target ye potenti exceed
modest ebitda margin expans potenti
improv
brought inventiv merger
addit larg contract win syneo one
leverag commerci servic inventiv
small-cap client access inc research
synergi relat merger inventiv health
growth pharma budget and/or amount
work outsourc
pleas see import disclosur inform page report
compani data jefferi llc
pleas see import disclosur inform page report
jefferi group except total servic direct reimburs oop forex- adj ebitdaadj total adj interest incom incom expens pre-tax adj net adj dilut common size oop incom incom net changetot incom net b/f healthearn model equiti research
syneo health lead global contract research organ cro provid full rang phase phase iv clinic
develop servic biopharmaceut medic devic industri signific breadth servic offer depth
therapeut expertis across multipl patient popul compani connect custom clinic research site patient
acceler deliveri new medicin market compani rank top cro work among larg global cro
centerwatch global investig relationship survey inc research headquart raleigh staff
countri experi span countri
pt reflect peer-referenc multipl ep risk project cancellations/delay merger integr
failur penetr new client price pressur new exist client
pt base ep line consensu ep compar basi peer risk project
cancel slowdown biotech fund slow backlog convers rate
pt reflect multipl premium peer ep risk includ integr technolog integr
synergi realiz contract cancel book volatil fx
pt reflect peer-referenc multipl ep assign higher multipl compar peer group due fastest
revenu growth group expand margin upsid cross-sel synergi data solut core busi risk
larg client loss project cancel margin pressur increas client
david windley cfa certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
danlei yan certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
jefferi llc act exclus financi advisor health scienc acquisit symphoni health solut
jefferi group llc make market secur adr syneo health
jefferi group llc make market secur adr icon plc
jefferi group llc make market secur adr
pleas see import disclosur inform page report
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate
secur averag secur price consist expect total return price appreci plu yield plu minu
within period under-perform rate secur averag secur price consist expect
total return price appreci plu yield minu less within period
nr invest rate price target temporarili suspend suspens complianc applic
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic
secur regul prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project
opinion invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ
restrict analys market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash
price-to-earnings sum part net asset valu dividend return return equiti roe next month
jefferi franchis pick includ stock select among best stock idea equiti analyst month period
stock select base fundament analysi may take account factor analyst convict differenti
analysi favor risk/reward ratio invest theme jefferi analyst recommend jefferi franchis pick
includ buy rate stock number vari depend analyst recommend inclus stock ad
new opportun aris remov reason inclus chang stock met desir return longer rate
buy and/or trigger stop loss stock day volatil bottom quartil stock continu
stop loss remaind stop franchis pick intend repres recommend portfolio stock
sector base may note believ pick fall within invest style growth valu
risk may imped achiev price target
report prepar gener circul provid invest recommend specif individu investor
financi instrument discuss report may suitabl investor investor must make
invest decis base upon specif invest object financi situat util financi advisor
deem necessari past perform financi instrument recommend report taken indic
guarante futur result price valu incom financi instrument mention report rise well
fall may affect chang econom financi polit factor financi instrument denomin currenc
investor home currenc chang exchang rate may advers affect price valu incom deriv
financi instrument describ report addit investor secur adr whose valu affect
currenc underli secur effect assum currenc risk
compani mention report
pleas see import disclosur inform page report
